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ABSTRACT Akeychallengeinmanagingtransmissiblespongiformencephalopathies(TSEs)orpriondiseasesinmedicine,agri-
culture,andwildlifebiologyisthedevelopmentofpracticaltestsforprionsthatareatorbelowinfectiouslevels.Ofparticular
interestaretestscapableofdetectingprionsinbloodcomponentssuchasplasma,butbloodtypicallyhasextremelylowprion
concentrationsandcontainsinhibitorsofthemostsensitivepriontests.Oneofthelattertestsisquaking-inducedconversion
(QuIC), which can be as sensitive as in vivo bioassays, but much more rapid, higher throughput, and less expensive. Now we
haveintegratedantibody15B3-basedimmunoprecipitationwithQuICreactionstoincreasesensitivityandisolateprionsfrom
inhibitorssuchasthoseinplasmasamples.Couplingofimmunoprecipitationandanimprovedreal-timeQuICreactiondra-
maticallyenhanceddetectionofvariantCreutzfeldt-Jakobdisease(vCJD)braintissuedilutedintohumanplasma.Dilutionsof
1014-fold,containing~2attogram(ag)permlofproteinaseK-resistantprionprotein,werereadilydetected,indicating~10,000-
foldgreatersensitivityforvCJDbrainthanhaspreviouslybeenreported.Wealsodiscriminatedbetweenplasmaandserum
samplesfromscrapie-infectedanduninfectedhamsters,eveninearlypreclinicalstages.Thiscombinedassay,whichwecall“en-
hancedQuIC”(eQuIC),markedlyimprovesprospectsforroutinedetectionoflowlevelsofprionsintissues,ﬂuids,orenviron-
mentalsamples.
IMPORTANCE Transmissiblespongiformencephalopathies(TSEs)arelargelyuntreatableandaredifﬁculttodiagnosedeﬁnitively
priortoirreversibleclinicaldeclineordeath.ThetransmissibilityofTSEswithinandbetweenspecieshighlightstheneedfor
practical tests for even the smallest amounts of infectivity. A few sufﬁciently sensitive in vitro methods have been reported, but
mosthavemajorlimitationsthatwouldprecludetheiruseinroutinediagnosticorscreeningapplications.Ournewassayim-
provestheoutlookforsuchcriticalapplications.Wefocusedinitiallyonbloodplasmabecauseapracticalbloodtestforprions
wouldbeespeciallyvaluableforTSEdiagnosticsandriskreduction.VariantCreutzfeldt-Jakobdisease(vCJD)inparticularhas
beentransmittedbetweenhumansviabloodtransfusions.Enhancedreal-timequaking-inducedconversion(eQuIC)providesby
farthemostsensitivedetectionofvCJDtodate.The15B3antibodybindsprionsofmultiplespecies,suggestingthatourassay
maybeusefulforclinicalandfundamentalstudiesofavarietyofTSEsofhumansandanimals.
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T
he transmissible spongiform encephalopathies (TSEs) or
prion diseases are fatal neurodegenerative disorders that in-
clude human Creutzfeldt-Jakob disease (CJD), bovine spongi-
form encephalopathy (BSE), sheep scrapie, and cervid chronic
wasting disease (CWD). The TSE infectious agent, or prion, is
composed primarily of an abnormal, misfolded, multimeric, and
usually partially protease-resistant form of the host’s prion pro-
tein(e.g.,PrPres,PrPvCJD,andPrPSc),whichcaninduce,orseed,its
own propagation by recruiting and converting the normal
protease-sensitive prion protein, PrPC (1). For brevity we will use
the term “prion” to refer to either TSE infectivity or TSE-
associated PrP seeding activity, bearing in mind that the two ac-
tivities may not always be strictly proportional to one another.
The apparent lack of prion-speciﬁc nucleic acid genomes,
polypeptides,orimmuneresponseshaspreventedtheuseofmost
conventional means for detecting pathogens and diagnosing in-
fections. Moreover, the unusual stability of prions makes decon-
tamination difﬁcult. Presymptomatic detection of prion infec-
tions in individuals will be critical in expediting potential
treatments and preventing further transmissions. In various
mammalianhosts,prionscanbefoundinawidevarietyoftissues
and accessible bodily ﬂuids, including blood (2–7), saliva (4, 8),
and nasal ﬂuids (9, 10). These materials not only have potential
diagnostic value, but also can be sources of TSE contagion. Of
particularconcernisthesafetyofthebloodsupply(11,12)dueto
transfusion-based transmissions of BSE and scrapie in sheep (13)
and of variant CJD (vCJD) in humans (14–16). The prevalence of
subclinical vCJD infections is far from clear but may be as high as
1 per 4,000 in certain United Kingdom age cohorts (http://www
.seac.gov.uk/papers/104-2.pdf). Unfortunately, the typically low
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usually prevented rapid detection. In scrapie-affected hamsters,
for example, blood contains only ~13 infectious doses per millili-
ter (17).
A number of in vitro methods for detecting minimally infec-
tiousorsubinfectiousamountsofprionshavebeenreported(5,6,
10, 18–32), but most have limitations that would preclude their
widespread use in routine diagnostic or screening applications.
Among the most rapid of the ultrasensitive prion tests are the
quaking-induced conversion (QuIC) reactions (20, 24), in which
prions induce the polymerization of recombinant PrPC (rPrPC)
into amyloid ﬁbrils. The original format (herein called “standard
QuIC” [S-QuIC]) involved tube-based reactions and immuno-
blottingofprotease-resistantrPrPconversionproducts(9,10,20,
24). A higher-throughput format, called “real-time QuIC” (10,
32), or RT-QuIC, employs multiwell plates and a thioﬂavin T
(ThT)-based ﬂuorescence detection of the prion-seeded amyloid,
ashasbeendescribedformanyotheramyloidseedingassays(e.g.,
references 22 and 33). RT-QuIC sensitivity rivals that of animal
bioassays and allows detection of prions endogenous to cerebro-
spinal ﬂuid (CSF) and nasal ﬂuids (10, 32). Moreover, in an end-
point dilution mode, the RT-QuIC can be quantitative (10). The
original RT-QuIC has been shown recently to have 80% sensi-
tivity and 100% speciﬁcity in discriminating between sporadic
CJD (sCJD) and non-CJD patients based on CSF samples (32).
Here we show that the combination of prion/PrPSc immuno-
precipitation (IP) with the S-QuIC and RT-QuIC prion ampliﬁ-
cation assays (IP-S-QuIC and IP-RT-QuIC, respectively) mark-
edly improves their sensitivities and applicability to the detection
of prions in dilute, inhibitor-laden ﬂuids such as blood plasma.
The IP step employs the PrP aggregate-speciﬁc monoclonal IgM
antibody 15B3 (34–36). When coupled with a substrate replace-
ment step, the IP-RT-QuIC assay is orders of magnitude more
sensitive than previously described tests for vCJD (30, 37).
RESULTS
Immunoafﬁnity capture of prions from blood plasma. To de-
velop a blood test for prions, we initially attempted to detect pri-
onsspikedintohumanandsheepplasmasamplesbydirectlyadd-
ing spiked plasma to S-QuIC and RT-QuIC reaction mixtures.
However, plasma components strongly inhibited both assays
(data not shown), consistent with previously reported inhibition
of protein misfolding cyclic ampliﬁcation (PMCA) (38) and ﬂow
cytometric assays (23). Accordingly, we sought methods to cap-
ture and concentrate prions in a detectable form from plasma.
Prionimmunoafﬁnitybeadswerepreparedbycouplingmonoclo-
nal antibody 15B3 (34) to magnetic beads. This antibody selec-
tively binds PrPres and other PrP oligomers but not monomeric
PrPC (34, 36). The ability of 15B3-coupled beads to immunopre-
cipitate prion activity from plasma was ﬁrst tested with the
S-QuIC assay. We spiked 0.5 ml of human plasma with hamster
scrapie and human vCJD brain homogenate dilutions or compa-
rable TSE-negative brain homogenates and incubated them with
the beads. The beads were then washed, added directly to the
S-QuIC reaction, and subjected to cycles of shaking and rest. As
described previously (20, 21, 24), positive prion-seeded S-QuIC
reactions were indicated by the characteristic pattern of 17-, 13-,
12, and 11-kDa proteinase K-resistant products [called rPrP-
res(Sc)] in immunoblots. We performed two-round reactions by
seeding aliquots of ﬁrst-round reaction products into fresh rPrPC
substrate. Control (mock) beads coated only with anti-IgM anti-
bodies (without 15B3) had some afﬁnity for prions, as indicated,
forexample,bythepositiverPrP-res(Sc)productsgeneratedinone
of the two replicate single-round reaction mixtures seeded with
beads incubated with plasma spiked with a 1  109 dilution of
scrapie brain homogenate containing ~100 fg PrPres (see the lane
marked by the asterisk in Fig. S1a in the supplemental material).
However, 15B3-coated beads were ~100-fold more efﬁcient at
capturing lower levels of prions from plasma, enabling detection
of dilutions containing 1f gP r P res (Fig. S1a and b). This IP-S-
QuIC protocol gave positive reactions from as little as 4  1010
dilutions of vCJD brain homogenate containing ~10 fg of human
PrPres (Fig. 1) and 2  1011 dilutions of scrapie hamster brain
containing ~1 fg of PrPres (Fig. S1). In contrast, no positive rPrP-
res(Sc) reaction products were obtained in reactions seeded with
FIG1 IP-S-QuICdetectionof10fghumanvCJDPrPresspikedintohuman
plasma. Dilutions of human nonprion (tumor [T]) control or vCJD brain
homogenates were spiked into 500 l of human plasma to give ﬁnal tissue
dilutions of 4  107 (T) and 4  107,4 109, and 4  1010 (vCJD;
containing ~10 pg, 100 fg, and 10 fg PrPres, respectively). PrPvCJD was immu-
noprecipitated and subjected to S-QuIC as described in Materials and Meth-
ods. The ﬁrst S-QuIC round was at 50°C for 8 h (a), and one-tenth of the
ﬁrst-roundreactionvolumewasusedtoseedthesecondround(45°Cfor10h)
(b). Plasma-free positive and negative control reaction (Rxn ctrls) mixtures
wereseededdirectlywith2lof5107dilutionsofhamsteruninfected(N)
or scrapie (Sc) brain, the latter containing ~100 fg PrPres seed. Hamster
rPrPC23–231 was used as a substrate in all reactions and comigrated with the
25-kDa marker. PK-digested products were analyzed by immunoblotting us-
ingthepolyclonalR20antibodyaspreviouslyreported(24).Opencirclesmark
17-kDafragments,andbracketsindicatethelower-molecular-massbands(10
to 13 kDa).
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IP-S-QuIC detected prion activity naturally present in 0.5 ml of
plasma from nine near-terminal scrapie-infected hamsters, while
no positive S-QuIC reactions were seeded by plasma from a neg-
ative control hamster in two-round reactions (Fig. 2).
15B3 IP of prions in plasma for detection by RT-QuIC (IP-
RT-QuIC). Because of the greater potential for high-throughput
testing, we then focused mainly on adapting the 15B3 IP to detec-
tion by RT-QuIC (designated IP-RT-QuIC). The RT-QuIC assay
uses intermittent shaking of reactions in 96-well plates, rPrPc as
the substrate, virtually detergent-free (0.002% SDS) and
chaotrope-free conditions, and ThT-based detection of prion-
seeded amyloid ﬁbrils (10, 32). Positive reactions are indicated by
an enhancement of ThT ﬂuorescence in the presence of rPrP am-
yloid ﬁbrils, which we plot as the average ﬂuorescence from rep-
licatewells.Inscreeningforconditionsthatallowthedetectionof
prions captured on 15B3 beads from blood plasma with the RT-
QuIC assay, we found that preincubation of the prion-bound
beadswith0.05%SDSfor~20minatroomtemperature,inaddi-
tion to a Sarkosyl wash of the beads, accelerated prion ampliﬁca-
tion in the otherwise detergent-free RT-QuIC (see Fig. S2 in the
supplemental material).
TheIP-RT-QuICprotocoldetected~1010dilutionsofscrapie
braininhumanplasma(datanotshown),butwaslesssensitivefor
vCJD brain (see Fig. S3C in the supplemental material). For de-
tection of scrapie, we used hamster rPrPC comprising residues 90
to 231 (rPrPC90–231) as a substrate. For vCJD, we found that a
chimeric rPrPC molecule, comprised of Syrian hamster residues
23 to 137 followed by sheep residues 141 to 234 (R154 Q171 poly-
morph), provided for greater sensitivity and less spontaneous
(prion-independent) conversion to ThT-positive products than
wasobservedwiththehomologoushumanPrPC23–231construct
(Fig. S3).
Using the hamster rPrPC90–231 substrate,15B3 IP of PrPSc
endogenous to 0.5 ml plasma or serum from scrapie-affected
hamsters yielded some, but usually not all, positive replicate reac-
tions, indicating that the PrPSc levels in these samples were at or
near the detection limit (Fig. 3). Collectively, these initial results
showed that 15B3 beads captured highly diluted prions from
plasma or serum in a manner compatible with both S-QuIC or
RT-QuIC detection, but the sensitivity of IP-RT-QuIC was bor-
derline for detection of prions endogenous to scrapie hamster
plasma.
eRTQ detection of 15B3-captured prions with substrate re-
placement. To improve the sensitivity of IP-RT-QuIC we intro-
duced a substrate replacement step after ~24 h of the RT-QuIC
reaction. In IP-RT-QuIC reactions, the beads and associated pri-
ons or prion-induced RT-QuIC conversion products tended to
adhere to the bottom of reaction wells. Thus, reaction ﬂuid could
be removed and fresh rPrPC added while retaining most of the
beads and bead-bound reaction products in the well. This combi-
nation of IP and RT-QuIC with substrate replacement, which we
call “enhanced RT-QuIC” (eQuIC), allowed detection of 4 
1014 dilutions of vCJD brain tissue (~1 attogram [ag] vCJD
PrPres) within ~28 h in all replicate reactions (n  4) in three
independentexperiments(e.g.,Fig.4A;seeFig.S4Ainthesupple-
mental material) performed using four different lots of human
plasma. With a further 4  1015 dilution, three of four replicate
reactions were positive in a single experiment (data not shown).
By comparison, Alzheimer’s and tumor brain negative control
dilutionsgaveuniformlynegativereactionsineachoftheseeQuIC
experiments. Mock beads lacking 15B3 gave much reduced sensi-
FIG2 DetectionofendogenousPrPScinplasmaofscrapie-infectedhamstersbyIP-S-QuIC.(a)Plasmasamplesfromscrapie263K-infectedanduninfected(N)
hamsters(500l)weresubjectedtoIP-SQasdescribedinMaterialsandMethodswiththeﬁrstroundofS-QuICat50°Cfor10handthesecondround(b)at50°C
for8h,exceptforlanesmarkedwithasterisks,whichshowtheﬁrst-roundproductsseededwithsampleno.6forcomparison.Plasma-freepositiveandnegative
controlreactions(Rxnctrls),rPrPC23–231substrate,andanalysisofPK-digestedproductswereasdescribedforFig.1.Opencirclesmark17-kDafragments,and
brackets indicate the lower-molecular-mass bands (10 to 13 kDa).
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beads provided for 106-fold more sensitive eQuIC detection
thansuperparamagneticnanoparticlesthatwerereportedrecently
to have prion-binding capacity (39) (Fig. S4). These results
showed the ability of the 15B3-based eQuIC to detect extremely
low concentrations of prions spiked into human plasma.
eQuIC detection of endogenous prions in hamster plasma
samples. We also tested if eQuIC improved the detection of pri-
ons endogenous to plasma from scrapie-infected hamsters. In
contrast to the earlier results with the unenhanced RT-QuIC
(Fig. 3), all of the replicate eQuIC reactions from a total of 13
scrapiehamsterswerepositive,whilenoneofthosefrom11unin-
fected hamsters were positive within 65 h (Fig. 5). Of the scrapie-
infectedhamsters,ninewereclinicallyaffected(80dayspostinfec-
tion [dpi]), and four were subclinically affected (3 at 30 dpi and 1
at 10 dpi). Thus, eQuIC detected prions in plasma long before
clinicalsignsofscrapie,whichinthismodelbeginat~60dpi.With
some scrapie samples the replicate wells, although all individually
positive, gave submaximal average ﬂuorescence values (Fig. 5a).
Thisvariability,aswellaslag-phasevariability,appearedtobedue
to aggregated plasma components because these variations were
notseenwithsamplesthatwerepreclearedbybriefcentrifugation
immediately prior to immunoprecipitation (Fig. 5b).
DISCUSSION
Collectively, these results showed that prions can be captured
fromacomplexinhibitor-ladenbiologicalﬂuidinamannerthatis
compatible with ultrasensitive detection by in vitro prion ampliﬁ-
cation assays. The eQuIC assay in particular provides a practical,
high-throughput, and rapid means of testing for amounts of
PrPres(e.g.,1ag)thatareseveralordersofmagnitudebelowthose
typically required to cause prion disease by intracerebral inocula-
tion into animals. The ability of eQuIC to detect prions in plasma
samples raises the possibility that this assay could be used to im-
FIG3 IP-RT-QuICdetectionofendogenousPrPScinplasmaandserumofscrapie-infectedhamsters.(a)IP-RT-QuICanalysesofplasmasamplesfromascrapie
263K-infected hamster and a normal hamster, and a serum sample from a scrapie 263K-infected hamster. (b) Analyses of plasma samples from nine scrapie
263K-infectedhamstersandoneuninfectedhamster.Inallcases,500-lsampleswereimmunoprecipitatedusing15B3-coatedbeadsfor~20hat37°C.One-ﬁfth
ofthebeadswerepreincubatedwith0.05%SDSinPBSatroomtemperaturefor~20minandusedtoseedRT-QuICcontaining300mMNaCl.RT-QuICreaction
mixtureswereincubatedat42°C,andhamsterrPrPC90–231wasusedasasubstrateinallreactions.Theverticalaxesindicatetheaverageﬂuorescencefromfour
replicate reaction wells. Error bars show standard deviations for selected sets of replicates in panel a. In panel b, all individual reactions that registered positive
ﬂuorescenceachievednearlyidenticalmaximalﬂuorescencevalues(~260,000U),butinmanyofthescrapie-seededcases,onlyasubsetofreplicatereactionsrose
above background ﬂuorescence within 63 h. With such all-or-nothing responses among replicates, it is of little value to calculate standard deviations from all of
the replicates; instead, on the right, we indicate the fraction of positive wells per total number of replicates at the end of the reactions. Error bars representing
standard deviations calculated for the positive replicates (only) barely, if at all, exceeded the sizes of the symbols and therefore are not shown.
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screen the blood supply for prion contamination. We have dem-
onstrateddiscriminationofscrapie-infectedanduninfectedham-
stersbasedoneQuICanalysisoftheirbloodplasmasamples;thus,
theassayhasatleastsomecapabilitytodetectnaturalblood-borne
prion seeding activity. However, although we have also shown
extremesensitivityoftheeQuICindetectingbrain-derivedspikes
of vCJD into human plasma, the sensitivity of eQuIC detection of
vCJD seeding activity that is endogenous to plasma remains to be
determined. We focused initially on plasma because it is a main
targetﬂuidforthedevelopmentofaninvivovCJDtest.However,
as 5- to 10-fold more CJD infectivity has been found in leukocyte
fractions of blood (40), it is possible that somewhat greater sensi-
tivity could be obtained by eQuIC analysis of leukocytes. 15B3-
based prion capture might also enhance the utility of other prion
ampliﬁcation assays. Ultimately, it will be important for TSE sur-
veillance labs to have multiple assays at their disposal so that pos-
itive tests can be reevaluated by other types of tests.
The two-stage substrate addition that we describe here for the
eQuIC differs from serial (multiple-round) ampliﬁcation steps
that have been described previously for protein misfolding cyclic
ampliﬁcation (PMCA) (5, 18), rPrP-PMCA (21), and QuIC (20,
24) reactions because most of the bead-bound prions and prion-
seeded products are retained in the reaction vessel so that the
substrate can be replaced without removing most of the seed par-
ticles. In contrast, in serial PMCA and S-QuIC reactions, only a
smallproportion(typically10%)ofthetotalreactionmixtureis
transferred to a new vessel containing fresh substrate, so that
much of the seeding activity from the ﬁrst round is lost.
The mechanistic basis for the dramatic improvements in assay
time and sensitivity due to the substrate replacement is not yet
clear, but our results suggest that at least two processes are occur-
ring during the initial lag phase of the eQuIC reaction, i.e., be-
tween the addition of seed and substrate replacement (Fig. 6).
First, the rPrPC must be moving into a pool that is less rapidly
accessible to prion-seeded ﬁbril assembly, such as an off-pathway
oligomer (OO); otherwise, the addition of fresh rPrPC after 20 h,
but before the initial substrate is converted to detectable ThT-
positive ﬁbrillar products, would not accelerate the reaction. We
suggest a “less rapidly accessible” pool rather than an inaccessible
FIG 4 eQuIC detection of human PrPvCJD spiked into human plasma. Dilutions of human nonprion (tumor and Alzheimer’s disease) control or vCJD brain
tissues were spiked into 500 l of human plasma to give ﬁnal dilutions of 4  107 (tumor and Alzheimer’s disease) and 4  1012,4 1013, and 4  1014
(vCJD;containing~100,10,and1agPrPres,respectively).PrPvCJDwasimmunoprecipitatedwith15B3-coatedbeads(a)ormockanti-IgM-coatedbeads(b),and
a portion of the beads were used to seed replicate eQuIC reaction mixtures containing 400 mM NaCl. After 24 h, the substrate was replaced. The chimeric Ha-S
rPrPC was used as a substrate in all reactions. The vertical axes indicate the average ﬂuorescence from four replicate wells, and the fractions on the right indicate
the positive/total replicate reactions associated with the adjacent traces.
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jority of the substrate can still be converted if given enough time.
Second,theinitialseedmustbebeingalteredandprimedinsome
way to seed more rapid ﬁbril assembly upon the addition of fresh
substrate; otherwise, it would have been capable of seeding rapid
ThT-positive rPrP-res(Sc) assembly at the beginning of the reac-
tion, when there was the same concentration of fresh substrate.
This priming effect might be explained by secondary nucleation
mechanisms(41,42),suchasthosemarkedwithredstarsinFig.6.
For example, during the lag phase, prion seeds may elongate by
incorporating rPrPC at a relatively slow and largely undetected
rate determined in part by the concentration of seed particles.
Withcontinuedelongation,theseededrPrPﬁbrilswouldbecome
long enough to be sheared by agitation, increasing the seed parti-
cle concentration and accelerating overall ﬁbril assembly. More-
over, other types of ﬁbril-dependent secondary nucleation might
contribute to the acceleration of ﬁbril assembly. For instance, ﬁ-
bril assembly might be hastened by the prealignment or scaffold-
ing of rPrPC substrate or amyloidogenic intermediate (AI) along
the sides of an existing ﬁbril, either with or without the need for a
similarlyalignedseed.Inanycase,furtherstudieswillberequired
to deﬁne the mechanistic underpinnings of the effects of two-
phase substrate addition.
As we have seen before with the S-QuIC assay (24), the best
rPrPC substrate for the RT-QuIC is not always the one that is the
mosthomologouswiththetypeofprion/PrPresbeingassayed.For
example, we were surprised to ﬁnd that the substrate that worked
best for the detection of human vCJD was the chimeric hamster-
sheep construct (Ha-S rPrPC) rather than a human rPrPC mole-
cule. The reasons for this are not clear, but may relate to factors
such as (i) the relative tendencies of the rPrPC to be consumed by
off-pathway changes that remove substrate from the assembly-
FIG 5 eQuIC detection of endogenous PrPSc in plasma of scrapie-infected hamsters. (a) eQuIC analysis of plasma samples (without preclearing) from eight
uninfectedhamstersandsixscrapie-infectedhamsters,withonecollectedat30dpi(preclinical)andﬁveat80dpi(near-terminal).Theverticalaxisindicatesthe
average ﬂuorescence from four replicate wells, and the fractions on the right indicate the positive/total replicate reactions associated with the adjacent traces.
Althoughallreplicatereactionsseededwiththescrapiesampleswerepositive,submaximalaverageﬂuorescencewasobservedforthreeofthesamplesat60h.In
thelattercases,thebeaddistributioninthewellpartiallyinterferedwithﬂuorescencereadings;whensuchwells(n3)wererereadat64haftermanualstirring
with a pipette, the ﬂuorescence achieved maximal levels (gray trace). In contrast, stirring of uninfected control wells (n  4) did not increase their ﬂuorescence.
HamsterrPrPC90–231wasusedasasubstrate.(b)eQuICanalysisofpreclearedplasmasamplesfromthreeuninfectedandsevenscrapie-infectedhamsters(three
collected at 80 dpi, two at 30 dpi, and one at 10 dpi).
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bril formation (i.e., false positives) or (ii) differences in propensi-
ties to form an amyloidogenic precursor or intermediate which
interacts most favorably with prion seeds (Fig. 6). Such a precur-
sor may be distinct from native rPrPC, as has been described for
othertypesofseededpolymerizationsofPrPC(43–45).Thesefac-
tors are likely to be condition dependent and, for the practical
purposes of detecting vCJD PrPres, appear to override problems
associated with sequence mismatches between the vCJD seed and
the Ha-S rPrPC substrate.
The eQuIC assay offers advantages compared to other cur-
rentlyestablishedultrasensitiveprion/PrPScassays.Relativetothe
ﬁrst-generation RT-QuIC assay, the eQuIC not only allows for
prion detection in inhibitor-laden samples such as plasma, but
alsoenhancesthesensitivityforvCJDbrainhomogenatedilutions
into human plasma by at least 10,000-fold. Compared to PMCA
reactions that have been described, the eQuIC is more rapid for a
givensensitivitylevel,morepracticalbyusingbacteriaratherthan
brain as the source of PrPC substrate, more easily replicated by
usingshakingratherthansonication,andmoreamenabletohigh-
throughput analyses due to multiwell-plate-based reactions and
ﬂuorescencedetection.Fluorescenceplatereadersshouldbemore
commonly available than the specialized instrumentation re-
quiredforsomeothertests(25–29).Recently,Edgeworthandcol-
leagues described a new vCJD PrPres detection assay which in-
cludes prion capture on stainless steel beads and an enzyme-
linked immunosorbent assay (ELISA) detection method (30).
Whereas this capture ELISA detected 1010-fold dilutions of vCJD
brain in whole blood, our eQuIC assay detected 1014-fold dilu-
tions in plasma. The Edgeworth assay detected PrPvCJD in blood
from 15 symptomatic patients with ~70% sensitivity and 100%
speciﬁcity,whichisnearlyaseffectiveastheRT-QuICindiagnos-
ing sporadic CJD by using CSF samples (32). However, the
~10,000-fold greater sensitivity of the eQuIC in detecting brain-
derived vCJD seeding activity suggests that it has considerable
potential to improve the sensitivity of vCJD and sCJD diagnosis
usingblood,plasma,CSF,orothersamples.However,wehavenot
yet gained access to vCJD patient plasma or CSF samples, and
further studies will be required to assess the diagnostic utility of
eQuIC based on the detection of vCJD seeding activity that is
endogenous to these and other specimens. The remarkable resis-
tance to inactivation of prions relative to other pathogens also
makes it important to develop practical assays for prion contam-
ination in a wide variety of materials, such as foods, feeds, trans-
planted tissues, medical devices, agricultural wastes and by-
products, soils, water sources, and other environmental samples.
FIG 6 Potential mechanisms of substrate replacement effect.
Prion Disease Blood Test
May/June 2011 Volume 2 Issue 3 e00078-11
® mbio.asm.org 7The ability to immunoprecipitate prions from complex matrices
and detect them with high sensitivity should foster the further
development of such assays.
MATERIALS AND METHODS
Recombinant prion protein puriﬁcation. Syrian golden hamster (resi-
dues 23 to 231; accession no. K02234), human (residues 23 to 231; acces-
sion no. M13899.1) rPrPC and hamster-sheep chimera rPrPC (Syrian
hamster residues 23 to 137 followed by sheep residues 141 to 234 of the
R154 Q171 polymorph [accession no. AY907689]) were ampliﬁed and li-
gated into the pET41 vector (EMD Biosciences), and sequences were ver-
iﬁed. Protein expression and puriﬁcation were performed as previously
described (10, 20, 21, 24). Purity of rPrPC proteins was 99%, as esti-
matedbySDS-PAGE,immunoblotting,andmassspectrometry(datanot
shown).
Plasma sample collection and tissue homogenate preparation. Syr-
iangoldenhamsterswereinoculatedintracerebrallywith50l0.5%brain
homogenate (BH) (Fig. 5) or 108-fold-diluted BH (Fig. 2 and 3) from
hamsters clinically affected with the 263K scrapie strain and held for the
designated time periods prior to brain tissue or blood collection. The
hamstersinoculatedwiththelowerdoseofscrapietooklongertobecome
ill, so tissues were collected from “near-terminal” hamsters at 103 to 116
dpi for Fig. 2 and 3 compared to 80 dpi for Fig. 5. For plasma collections,
hamsters were euthanized by deep isoﬂurane anesthesia and exsangui-
natedviaheartstick.BloodwasimmediatelytransferredtoBDVacutainer
(sodiumcitrate;Becton-Dickinson)tubeandmixedgently.Sampleswere
centrifuged at 3,000 rpm in a Beckman J6-HC centrifuge for 15 min.
Plasma was transferred to a new tube and stored at 80°C. Hamster
serum samples were collected in a similar fashion, but with no sodium
citrate. When designated (Fig. 5B), plasma samples were centrifuged at
16,000 relative centrifugal force (RCF) for 30 s after thawing and imme-
diatelypriortotheimmunoprecipitationstep(usingtheplasmasuperna-
tant). Pooled human plasma (Innovative Research) was stored at 20°C.
For brain BH dilution spiking experiments, human plasma aliquots were
thawed over night at 4°C and subjected to a 10-min 2,000  g spin to
eliminate precipitated fraction.
Hamster and human 10% (wt/vol) BH were made as previously re-
ported(18),aliquoted,andstoredat80°C.Forspikingexperiments,BH
wasseriallydilutedineither1%or0.1%SDSinphosphate-bufferedsaline
(PBS) with 130 mM NaCl and N2 medium supplement (Gibco) (20, 21,
24) for the S-QuIC and RT-QuIC assays, respectively. Two microliters of
the designated BH dilutions was used to spike 0.5 ml of human plasma.
15B3coatingofmagneticbeads.Ratanti-mouseIgMDynabeads(In-
vitrogen)werevortexedfor30s,and250lofbeads(1108totalbeads)
was transferred to a new tube for the coating procedure. Following incu-
bationonthemagnetfor2min,beadstoragebufferwasdiscardedandtwo
washes were performed with 5 original suspended bead volumes, using
coating buffer (0.1% bovine serum albumin [BSA] in PBS made fresh,
ﬁltered,andkeptat4°C).Aratioof1106beadspergof15B3antibody
(Prionics) was used. Tubes were incubated with “end-over-end” rotation
atroomtemperaturefor2h.Next,threemorewasheswithcoatingbuffer
were carried out, and beads were resuspended in coating buffer (initial
bead volume) and stored at 4°C. Mock control beads were prepared as
described for 15B3 beads but with no addition of 15B3 antibody.
Preparation of MagnaBind beads. MagnaBind beads (Pierce, Rock-
ford,IL)werevortexedfor30s,and1.2108totalbeadsweretransferred
to a new tube. The beads were rinsed twice with 500 l of 0.5% Triton
X-100 in PBS and resuspended in their initial volume with assay buffer
(Tris-buffered saline [TBS], 1% Triton X-100, 1% Tween 20).
Immunoprecipitation of 263K and vCJD PrPres in plasma. 15B3-
coatedbeads,mockbeads,orMagnaBindbeadswerebrieﬂyvortexed,and
1.6  107 total beads were transferred to a new tube. Following 2 min of
incubationonthemagnet,thestorage(coating)bufferwasdiscardedand
500lofimmunoprecipitationbuffer(Prionics)wasadded.Next,500l
ofBH-spikedhumanplasmaor500lofhamsterplasmafromuninfected
or scrapie-positive animals was added to the beads. Samples were incu-
bated with “end-over-end” rotation at room temperature or 37°C over-
night (ON). Subsequently, samples were incubated on the magnet for
2 min, plasma-buffer mix was discarded, and beads were washed twice
with 500 l of wash buffer (Prionics). All beads were resuspended into
10 l of PBS and used fresh.
S-QuIC and RT-QuIC. The S-QuIC assay was performed as previ-
ously described (20, 24). 15B3-coated- or mock bead S-QuIC reaction
mixtures were each seeded with 2 l of beads in PBS. The RT-QuIC was
performed as previously described (10), except for a few modiﬁcations.
Brieﬂy, 15B3-coated, mock, or MagnaBind beads from the immunopre-
cipitation step (resuspended in 10 l PBS) were combined with 0.05%
SDS–PBS (1:1 ratio) and incubated at room temperature for 20 min, and
reaction mixtures were seeded with 4 l of 0.05% SDS–PBS–bead mix.
RT-QuICreactionmixtureswereincubatedat46°Cunlessindicatedoth-
erwise in ﬁgure legends. Substrate replacement was performed by inter-
ruptingtheRT-QuICreactionafter24handspinningtheplateat3,000
g for 10 min at 4°C. Next, 90 l of supernatant was removed from each
well, taking care not to perturb the beads, and 100 l of new reaction
buffercontainingfreshrPrPCwasgentlyaddedtoeachwell.RT-QuICwas
continued for an additional 36 to 60 h.
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